Ascendis Pharma A/S Publishes ApproaCH Trial Week 104 Data Presentation

Reuters03-16 20:29
<a href="https://laohu8.com/S/ASND">Ascendis Pharma A/S</a> Publishes ApproaCH Trial Week 104 Data Presentation

Ascendis published a document summarizing Week 104 results from the pivotal ApproaCH trial open-label extension evaluating once-weekly navepegritide (TransCon CNP) in treatment-naïve children with achondroplasia aged 2 to 11 years. In the double-blind period, annualized growth velocity at Week 52 was 5.89 cm/year for navepegritide and 4.41 cm/year for placebo. The document also reports a least squares mean difference of 1.49 cm/year (95% CI: 1.05 to 1.93) for the Week 52 annualized growth velocity endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment